Aktis Oncology Stock

aktisoncology.comHealthcare / BioTech & PharmaFounded: 2019

Aktis Oncology is a biopharma solutions company that specializes in cancer care with novel platform technologies. Aktis Oncology uses powerful, radiopharmaceuticals to target therapies that harness alpha-emitting participles designed to optimize treatment options.

Register To Buy and Sell Shares

For more details on financing and valuation for Aktis Oncology, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Aktis Oncology’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Aktis Oncology.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Matthew Roden, PhD
President & Chief Executive Officer
Paul L. Feldman, PhD
Chief Scientific Officer
Pankaj Bhargava, MD
Interim Chief Medical Officer
Brian Goodman, PhD
Co-Founder & Chief Operating Officer
Ved Srivastava, PhD
Vice President, Head of Chemistry
Karen McCarthy
Executive Director, Head of Finance
Tyler Benedum, PhD
Senior Vice President, Head of Chemistry, Manufacturing, and Controls
Dasa Lipovsek, PhD
Vice President, Head of Lead Discovery
Kelly Polanco
Vice President, Head of People & Culture
Carlos Rodriguez
Executive Director, Corporate Development
Lorraine Horgan
Executive Director, Head of Program Management
Janet Horton, MD
Executive Director, Clinical Development

Board Members

Todd Foley
MPM Capital
Helen Kim, MBA
Vida Ventures
Oleg Nodelman
EcoR1 Capital
Lloyd M. Segal, MBA
Repare Therapeutics

Aktis Oncology’s stock FAQs


Can you buy Aktis Oncology’s stock?

Aktis Oncology is not publicly traded on NYSE or NASDAQ in the U.S. To buy Aktis Oncology’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Aktis Oncology’s stock?

Yes, you can sell stock of a private company like Aktis Oncology. Forge can help you sell your Aktis Oncology stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Aktis Oncology’s stock price?

Aktis Oncology is a privately held company and therefore does not have a public stock price. However, you may access Aktis Oncology’s private market stock price with Forge Data.

What is Aktis Oncology’s stock ticker symbol?

Aktis Oncology does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Aktis Oncology Nabs A Rare Upround of $84M In Extension Funding

Biotech firm Aktis Oncology announced Thursday it closed an $84 million extension round partially funded by large pharma companies like Merck, Bristol Myers Squibb and Novartis.
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.